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SUMMARY
2-Oxoglutarate-dependent dioxygenases, including the EglN prolyl hydroxylases that regulate HIF, can be
inhibited with drug-like molecules. EglN2 is estrogen inducible in breast carcinoma cells and the lone
Drosophila EglN interacts genetically with Cyclin D1. Although EglN2 is a nonessential gene, we found that
EglN2 inactivation decreases Cyclin D1 levels and suppresses mammary gland proliferation in vivo. Regula-
tion of Cyclin D1 is a specific attribute of EglN2 among the EglN proteins and is HIF independent. Loss of
EglN2 catalytic activity inhibits estrogen-dependent breast cancer tumorigenesis and can be rescued by
exogenous Cyclin D1. EglN2 depletion also impairs the fitness of lung, brain, and hematopoietic cancer lines.
These findings support the exploration of EglN2 inhibitors as therapeutics for estrogen-dependent breast
cancer and other malignancies.INTRODUCTION
Most successful drugs are small organic molecules that bind to,
and inhibit, specific cellular proteins. Proteins that serve as
enzymes have proven to be particularly tractable as drug targets.
Establishing additional classes of enzymes that can be manipu-
lated with small organic molecules opens new avenues for drug
discovery.
The 2-oxoglutarate and iron-dependent dioxygenase super-
family includes the collagen prolyl and lysyl hydroxylases, the
FTO and AlkB DNA demethylases, the JmjC-containing histone
demethylases, the FIH1 asparaginyl hydroxylase, and the EglN
family prolyl hydroxylases (Aravind and Koonin, 2001; Klose
et al., 2006; Pollard et al., 2008; Taylor, 2001). These enzymesCcan be inhibited with drug-like small molecules that compete
with 2-oxoglutarate or interfere with iron utilization, both in vitro
and in vivo (Bruegge et al., 2007; Mole et al., 2003; Ozer and
Bruick, 2007; Safran et al., 2006).
There are three EglN (also called PHD or HPH) family members
in humans, called EglN1, EglN2, and EglN3 (Kaelin and Ratcliffe,
2008). All three enzymes are capable of hydroxylating the
a subunit of the heterodimeric transcription factor HIF (hypoxia-
inducible factor). Prolyl hydroxylated HIFa is recognized by
a ubiquitin ligase complex containing the pVHL tumor-
suppressor protein, leading to its polyubiquitinylation and subse-
quent proteasomal degradation. EglN family members exhibit
Km values for oxygen that exceed the oxygen concentrations
found in mammalian tissues (Kaelin and Ratcliffe, 2008).SIGNIFICANCE
Cyclin D1 plays an important role in many cancers, including breast cancer. The observations described herein predict that
inhibiting EglN2 catalytic activity will diminish Cyclin D1 levels in cancer cells and impair their ability to proliferate in vivo.
Notably, EglN2 is estrogen inducible and loss of either EglN2 or Cyclin D1 leads tomammary gland hypoproliferation. There-
fore the relationship between EglN2 and Cyclin D1might be especially relevant in hormone-sensitive breast cancer, in which
new therapies are needed for women who become refractory to estrogen antagonists. EglN2 appears to be an attractive
drug target because EglN2 is not essential in mammals and it has already been established that enzymes of this class
can be inhibited with drug-like small organic molecules.ancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc. 413
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Control of Cyclin D1 and Tumorigenesis by EglN2Accordingly, these enzymes are highly sensitive to decrements in
oxygen availability, such as might occur following an interruption
in blood supply. HIF regulates a program of gene expression that
facilitates survival under hypoxic conditions through cell-intrinsic
changes in metabolism and cell-extrinsic changes affecting
oxygen delivery. For example, HIF activates the transcription of
genes such as erythropoietin that enhance red blood cell produc-
tion and hence blood oxygen carrying capacity. EglN antagonists
stimulate red blood cell production in mammals and are currently
undergoing phase II testing for different forms of anemia (Hsieh
et al., 2007; Safran et al., 2006).
EglN1 (also called PHD2) is the primary prolyl hydroxylase
responsible for HIF regulation (Berra et al., 2003; Minamishima
et al., 2008; Takeda et al., 2008). EglN2 (also called PHD1) and
EglN3 (also called PHD3) might also regulate HIF under certain
conditions (Appelhoff et al., 2004). For example, EglN3 is
itself a HIF target, is induced by hypoxia, and has a lower oxygen
Km than EglN1 (Appelhoff et al., 2004; Minamishima et al., 2009).
Cell culture and animal experiments support that EglN3 partially
compensates for EglN1 when the latter is inactivated by hypoxia
(Appelhoff et al., 2004; Minamishima et al., 2009). Whether EglN2
and EglN3 have HIF-independent functions is less clear,
although recent studies support a HIF-independent role for
EglN3 in the control of apoptosis (Rantanen et al., 2008; Schlisio
et al., 2008).
Polyak and coworkers reported that EglN2 mRNA accumu-
lates in breast cancer cells that have been stimulated to prolif-
erate with estrogen and that EglN2 overexpression promotes
estrogen-independent growth and tamoxifen resistance (Seth
et al., 2002). Frei and Edgar (2004) noted that certain phenotypes
observed in flies engineered to overproduce Cyclin D1 were
abrogated by concurrent inactivation of Egl9, which is the lone
ancestral EglN family member in Drosophila. Since Cyclin D1
Figure 1. EglN2 Regulates Cyclin D1
(A) Immunoblot analysis of HeLa cells 48 hr after
transfection with siRNAs targeting EglN1, EglN2,
EglN3, or a scrambled control siRNA.
(B, E, and F) Immunoblot (B) and qRT PCR (E and
F) analysis of U2OS and HeLa cells transfected
with two independent siRNAs (#1 and #4) targeting
EglN2 (asterisk indicates nonspecific bands). Error
bars represent one SEM.
(C) Immunoblot analysis of ZR 75 1 cells infected
with a lentivirus encoding an ARNT shRNA or
scrambled control (Scr) followed by transfection
with siRNA against EglN2 or scrambled control.
(D) Immunoblot analysis of UOK101 cells in
fected with a lentivirus encoding an HIF2a
shRNA or scrambled control (Scr) followed by
transfection with siRNA against EglN2 or scram
bled control.
plays an important role in many forms
of cancer, including breast cancer, and
is induced by estrogen in estrogen-
receptor positive breast cancers (Bart-
kova et al., 1994; Landis et al., 2006;
Roy and Thompson, 2006; Yu et al.,
2001), we asked whether EglN2 activity affects Cyclin D1
activity.
RESULTS
Toward this end, we transiently transfected HeLa cervical carci-
noma cells, U2OS osteosarcoma cells, and both T47D and
ZR-75-1 breast carcinoma cells with previously validated
siRNAs that are specific for EglN1, EglN2, or EglN3 (Appelhoff
et al., 2004). Downregulation of EglN2, but not EglN1 or EglN3,
decreased Cyclin D1 protein levels (Figure 1A, Figure S1A [avail-
able online], and data not shown). Similar results were observed
with a second, independent, EglN2 siRNA and downregulation of
Cyclin D1 by the two different EglN2 siRNAs mirrored their ability
to downregulate EglN2 (Figure 1B and Figure S1B). In some
experiments Cyclin D3 was also decreased (data not shown).
As expected, suppression of EglN1, but not EglN2 or EglN3,
induced HIF1a (Figure 1A). These results suggest that Cyclin
D1 is specifically regulated by EglN2 among the EglN family
members and that EglN2 regulates Cyclin D1 in a HIF-indepen-
dent manner.
In further support of the latter conclusion, downregulation of
Cyclin D1 after EglN2 loss was not affected by concurrent
inactivation of the HIFa heterodimeric partner ARNT (HIF1b)
(Figure 1C and Figure S2A). In addition, EglN2 loss decreased
Cyclin D1 in UOK101 and 769-P VHL/ renal carcinoma cells,
which constitutively produce HIF2a protein due to the absence
of pVHL and produce neither HIF1a mRNA nor protein (Maxwell
et al., 1999) (Figure 1D, Figure S2B, and data not shown). More-
over, elimination of HIF2a in these cells with a highly effective
short hairpin RNA (shRNA) did not prevent the loss of Cyclin
D1 in cells depleted of EglN2 (Figure 1D and Figure S2B). Collec-
tively, these results strongly suggest that the regulation of Cyclin414 Cancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc.
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Control of Cyclin D1 and Tumorigenesis by EglN2D1 by EglN2 is not mediated by changes in HIF activity. Note that
in some experiments EglN2 protein migrated as a doublet (for
example, Figure 1C), probably due to alternative translation
initiation (Tian et al., 2006).
Both EglN2 mRNA and Cyclin D1 mRNA levels were dimin-
ished in cancer cells transfected with EglN2 siRNA, but not in
cells transfected with a scrambled control siRNA (Figures 1E
and 1F and Figures S2C and S2D). Moreover, we have not de-
tected specific binding of EglN2 to Cyclin D1 and EglN2 failed
to hydroxylate Cyclin D1 in vitro (data not shown). Collectively,
these results suggest that the regulation of Cyclin D1 by EglN2
is indirect and involves changes in Cyclin D1 transcription or
mRNA stability.
To examine this further, we measured the levels of heteroge-
nous nuclear Cyclin D1 RNA, indicative of newly transcribed
mRNA precursors, and recruitment of RNA Polymerase II to
the Cyclin D1 promoter, indicative of on-going transcription, in
cells after EglN2 depletion. In both T47D and ZR-75-1 breast
carcinoma cells depletion of EglN2 with an effective shRNA
decreased heterogenous nuclear Cyclin D1 RNA levels (Figures
S3A–S3D) and decreased loading of RNA Polymerase II onto the
Cyclin D1 promoter (Figures S3E and S3F) relative to cells
treated with a scrambled control shRNA. In contrast, we did
not detect a difference in Cyclin D1 mRNA stability in cells that
were infected to produce either the EglN2 or control shRNA
and then treated with actinomycin to prevent new mRNA
synthesis (data not shown). Therefore the regulation of Cyclin
D1 by EglN2 is at least partly at the level of transcription.
EglN2/ mice are viable and grossly normal (Aragones et al.,
2008; Takeda et al., 2006). In keeping with the siRNA-based
experiments described above, we found that Cyclin D1 mRNA
and protein levels are diminished in EglN2/ mouse embryo
Figure 2. Decreased Cyclin D1 Levels in
EglN2 / Mice
(A and B) Immunoblot (A) and qRT PCR analysis
(B) of MEFs prepared from littermates with the
indicated genotypes. Error bars represents one
SEM.
(C) Whole mounts of mammary glands from wild
type and EglN2 / mice 1 day postpartum. Images
were taken at 63 magnification.
(D) Immunoblot analysis of mammary glands as
in (C).
fibroblasts (MEFs) (Figures 2A and 2B).
Moreover, we observed that older, preg-
nant EglN2/ mice do not breastfeed
their pups properly compared to litter-
mate controls, a phenotype previously
observed in Cyclin D1/ mice (Sicinski
et al., 1995). Moreover, mammary glands
from older, lactating EglN2/ mice re-
vealed evidence of hypoproliferation
reminiscent of, but not as severe as
seen in, Cyclin D1/ mice (Sicinski
et al., 1995) (Figure 2C) and exhibited
lower levels of Cyclin D1 protein (Fig-
ure 2D). Therefore, EglN2 regulates
Cyclin D1 in vivo, with loss of EglN2 leading to a hypomorphic
Cyclin D1 phenotype.
Since EglN2 mRNA is induced by estrogen in human breast
cancer cells (Appelhoff et al., 2004; Seth et al., 2002), and
EglN2 loss affects mammary gland proliferation, we next
focused our attention on the role of EglN2 in human breast
cancer. We first confirmed that EglN2 protein levels, like EglN2
mRNA levels, are induced by estrogen in human (T47D) breast
cancer cells (Figures 3A and 3B). Moreover, EglN2 mRNA levels
are increased in estrogen receptor (ER)-positive breast cancers
compared to ER-negative breast cancers (Figures 3C and 3D)
and Cyclin D1 mRNA and EglN2 mRNA levels are positively
correlated with one another across breast cancers (Figure S4).
In contrast, EglN1 mRNA levels appear to be highest in ER-nega-
tive, Her2-negative breast cancers and EglN3 mRNA levels
highest in ER-negative, Her2-positive breast cancers (Figure 3D).
Notably, both EglN1 and EglN3 are HIF targets. Although Her2
activation has been reported to activate HIF (Laughner et al.,
2001; Li et al., 2005) we observed the clearest evidence of
HIF activation, as determined by accumulation of canonical
HIF-responsive mRNAs, in the ER-negative, Her2-negative
breast cancers (A.L.R. and W.G.K., unpublished data).
Forced overexpression of EglN2 promotes colony formation
by T47D cells (Seth et al., 2002). Similarly, we found that overex-
pression of EglN2 was sufficient to promote the proliferation of
T47D cells in the absence of estrogen (Figures 3E and 3F). Exog-
enous EglN2 had only minimal effects on Cyclin D1 and prolifer-
ation in the presence of estrogen, however, presumably because
the endogenous EglN2 is no longer limiting under these condi-
tions (Figures 3E and 3F). To investigate whether EglN2 loss
would inhibit breast cancer cell proliferation, we infected T47D
cells with retroviral vectors encoding shRNAs corresponding toCancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc. 415
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Control of Cyclin D1 and Tumorigenesis by EglN2the two EglN2 siRNAs used above. Downregulation of both
EglN2 and Cyclin D1 by the EglN2 shRNAs, but not control
(scrambled GFP) shRNA, was confirmed by immunoblot analysis
(Figure 4A).
As expected, T47D cells infected with the control shRNA, like
parental T47D cells, proliferated in the presence of estrogen but
not in its absence (Figure 4B). Proliferation in the presence of
estrogen was markedly reduced, however, in T47D cells infected
with either of the two EglN2 shRNAs (Figure 4B). The effects of
EglN2 reduction on proliferation were even more striking in the
estrogen-dependent cell lines BT-474 (Figures 4C and 4D) and
ZR75-1 (Figures 4E and 4F).
The observation that two independent EglN2 shRNAs, but not
the control shRNA, inhibited cell proliferation argues that this
phenotype is due to effects on EglN2 activity (‘‘on-target’’). To
test this further, we performed rescue experiments using T47D
cells that were infected with a retrovirus encoding a nonnatural
EglN2 mRNA in which translationally silent mutations were
introduced into the sequence targeted by shRNA #4. These
cells, but not cells infected with an empty retrovirus, were now
insensitive to the Cyclin D1 suppressive (Figure 5A) and antipro-
liferative effects of the EglN2 shRNA #4 (Figure 5B). These find-
ings, together with our analysis of EglN2/ cells, support that
EglN2 regulates Cyclin D1-dependent cell proliferation.
In parallel, we tested cells producing a shRNA #4-resistant
EglN2 mRNA encoding a hydroxylase-defective EglN2 mutant
(EglN2 H358A) (Epstein et al., 2001; Figure S5). This mutant, in
which a canonical histidine residue within the EglN2 catalytic
domain has been replaced by alanine, did not rescue cyclin D1
levels (Figure 5A) and did not rescue proliferation in T47D cells
Figure 3. EglN2 Is Estrogen Inducible
(A and B) Immunoblot (A) and qRT PCR analysis (B) of T47D cells treated with estrogen or vehicle. Error bars represents one SEM.
(C) Normalized EglN2 mRNA levels in nine publically available mRNA expression profile data sets. Red boxes, ER positive breast cancers; blue boxes, ER nega
tive breast cancers. P values for these nine data sets are 1.2E 9; 3.4E 8; 6.2E 8; 1.1E 7; 2.1E 7; 6.3E 7; 1.4E 6; 5.6E 5; and 9.6E 5, respectively.
(D) Relative expression of EglN2 and other genes of interest in subsets of breast cancers as analyzed by gene expression array. Samples are arranged into
subsets according to immunohistochemistry (IHC) staining results for ER (blue indicates R1% positive nuclei and green indicates <1% positive nuclei) and
HER 2/neu (blue indicates HER 2/neu score of 3+ [strong complete membrane staining in >10% of cells] and green a HER 2/neu score of 0, 1, or 2+). The middle
panel is a display of the relative gene expression (red indicates high expression and blue indicates low expression) with each column representing an individual
tumor sample and each row representing the results for the indicated genes. Cyclin D1 (CCND1) mRNA levels are higher in ER positive tumors compared to
ER negative tumors (mean levels 500 versus 330 arbitrary units; p < 2E 8).
(E and F) Immunoblot analysis (E) and proliferation assay (F) of T47D cells infected with retrovirus encoding HA EglN2 or with the empty vector in the presence or
absence of estrogen (10 nM) treatment. In (E), estrogen exposure was for 48 hr prior to cell harvest and anti HA antibody was used to detect exogenous (Exo)
EglN2. Error bars represent one SEM.416 Cancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc.
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Control of Cyclin D1 and Tumorigenesis by EglN2infected to produce EglN2 shRNA #4 (Figure 5B). Similarly, the
retrovirus encoding wild-type EglN2, but not EglN2 H358A,
restored Cyclin D1 in EglN2/ MEFs (Figure 5C). It should be
noted that the EglN2 H358A has a shorter half-life than wild-
type EglN2 (Figure S6 and data not shown). Therefore, a higher
titer of the EglN2 H358A virus was used to achieve comparable
levels of wild-type and mutant EglN2 in Figures 5A and 5C. In
viral titration experiments wild-type EglN2 rescued Cyclin D1
levels over a wide range of titers, whereas mutant EglN2 did
not rescue at any titer tested (Figure S6 and data not shown).
Similarly, wild-type EglN2, but not EglN2 H358A, rescued
Cyclin D1 production in HeLa cells transiently transfected with
EglN2 siRNA #4 (Figure 5D). This effect was specific because
neither EglN1 nor EglN3 rescued Cyclin D1 levels when tested
in parallel (Figure 5D). In these experiments, EglN3, however, ap-
peared to be unstable, possibly due to polyubiquitinylation by
SIAH (Nakayama et al., 2004). Finally, endogenous Cyclin D1
levels were decreased in cells exposed to either hypoxia or small
molecule hydroxylase inhibitors (Figures 5E and 5F). Downregu-
lation of Cyclin D1 by hypoxia and hydroxylase inhibitors was
due, at least in part, to decreased Cyclin D1 mRNA levels and
was not an indirect consequence of activating the HIF transcrip-
tional response as it did not depend on the canonical HIFa
Figure 4. Downregulation of EglN2 Suppresses
Cancer Cell Proliferation
(A and B) Immunoblot (A) and cell proliferation assay (B) of
T47D cells infected with retrovirus encoding shRNA against
EglN2 (sequence 1 or 4) or a scrambled control shRNA. In
(B), cells were grown in Phenol red free RPMI medium supple
mented with 5% charcoal/dextran treated FBS in the pres
ence or absence of estrogen (10 nM) as indicated.
(C F) Immunoblot (C and E) and cell proliferation (D and F)
assay of BT474 (C and D) and ZR75 1 cells (E and F). Error
bars represent one SEM.
partner ARNT (HIF1b) (Figure 5F and Figure S7).
These results strongly suggest that regulation of
Cyclin D1 by EglN2 is linked to the ability of EglN2
to hydroxylate one or more substrates other
than HIF.
Cyclin D1 stimulates proliferation by promoting
the phosphorylation of the retinoblastoma protein
(pRB) and cells lacking pRB are inured to inhibitors
of Cyclin D1-associated kinase activity. Overex-
pression of Cyclin D1, like overexpression of
EglN2 itself, rescued cell proliferation in T47D cells
expressing an EglN2 shRNA (Figures 6A and 6B).
Moreover, the proliferation of breast cancer cells
lacking pRB function due to RB1 mutation (Figures
6C and 6D), exogenous expression of the E7 onco-
protein (Figures 6E and 6F), or exogenous expres-
sion of RB1 shRNAs (Figure S8) was not impaired
by EglN2 loss despite diminished Cyclin D1 levels.
These results support that impaired proliferation in
cells lacking EglN2 is due, at least partly, to loss of
Cyclin D1. We also noted that exogenous Cyclin D
levels were diminished by EglN2 in some experi-
ments (Figure 6A). The significance of this finding
is not yet clear but could reflect a posttranscriptional link
between EglN2 and Cyclin D1.
To determine whether EglN2 ablation would diminish cancer
cell proliferation or survival in other cell lineages, we obtained
multiple shRNA constructs targeting EglN2 from the RNAi
Consortium (TRC) at the Broad Institute. We confirmed that
each of these constructs effectively suppressed EglN2 (Fig-
ure 7A). We next examined data from a set of 12 cancer cell lines
that were screened with a pooled version of the TRC shRNA
library (Luo et al., 2008) to determine whether cells harboring
these EglN2-specific shRNAs were depleted from a population
of cells during 28 days. Indeed, we observed that cells expressing
EglN2-specific shRNAs were depleted from the population for
each of the cell lines tested. Specifically, we observed that these
constructs were depleted 2.8-fold on average with a maximum
depletion of 18.4-fold for construct #5 in the U251 cell line
(Figure 7B). EglN2 ranks in the top 16.5% (rank #1553/9423
genes) of depleted genes across all 12 cell lines as compared
to all genes examined in this pooled screen (Figure 7C). Together,
these observations support that EglN2 is essential for prolifera-
tion of cancer cell lines derived from multiple lineages.
To investigate whether downregulation of EglN2 would affect
tumor growth in vivo, we next infected ZR75-1 breast carcinomaCancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc. 417
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Control of Cyclin D1 and Tumorigenesis by EglN2cells with lentiviruses encoding EglN2 shRNAs (#1 or #4) under
the control of a doxycycline-inducible promoter. Cells infected
with an analogous lentivirus encoding a scrambled GFP shRNA
served as a control. As expected, doxycycline treatment of cells
infected with the EglN2 shRNA lentiviruses led to decreased
EglN2 and Cyclin D1 protein levels and decreased cell prolifera-
tion compared to cells grown in the absence of doxycycline
(Figures 8A and 8B). Cessation of proliferation in this model
was associated with an apparent G1/S block, consistent with
loss of Cyclin D1 function (Figure S9). These effects of doxycy-
cline were specific because they were not observed in cells
infected with the control shRNA lentivirus. Gene expression
profiling, combined with gene set enrichment analysis,
confirmed that EglN2 depletion led to downregulation genes
Figure 5. Control of Cyclin D1 and Prolifera
tion by EglN2 Is Hydroxylase Dependent
(A and B) Immunoblot (A) and cell proliferation
assay (B) of T47D cells that were first infected
with a retrovirus expressing an shRNA resistant
mRNA encoding wild type or catalytic dead
(H358) EglN2 (or with empty vector) and then in
fected with a EglN2 shRNA retrovirus (or scram
bled shRNA vector).
(C) Immunoblot analysis of EglN2 / MEFs in
fected with retroviruses encoding EglN2 (wild
type) or EglN2 H358A or with the empty vector.
An EglN2+/+ extract was included in lane 1 as
a control. Note that the EglN2 antibody does not
recognize murine EglN2.
(D) Immunoblot analysis of HeLa cells transiently
transfected with plasmids encoding the indicated
EglN proteins (or the empty vector) and siRNAs
against EglN2 or luciferase (GL3). The molecular
bases for the bands indicated by the asterisks
are unknown.
(E and F) Immunoblot analysis of ZR 75 1 cell (E)
and isogenic murine hepatoma cells (ARNT / or
ARNT+/+) (F) treated overnight with hypoxia
(0.2% O2), CoCl2 (200 mM), DFO (200 mM),
DMOG (1 mM) or FG0041 (40 mM). Error bars
represent one SEM.
linked to cell-cycle progression,
estrogen-dependent signaling, and
tamoxifen resistance (Figure S10 and
Tables S1–S3).
Next, the ZR75-1 cells infected with the
inducible shRNA lentiviruses were in-
fected with a retrovirus encoding lucif-
erase and grown orthotopically in the
mammary glands of immunocompro-
mised mice. The luciferase activity of
the EglN2 shRNA cells was comparable
to the luciferase activity of the control
shRNA cells in vitro (data not shown).
One mammary gland was injected with
the inducible EglN2 shRNA cells and the
contralateral mammary gland was in-
jected with the inducible control shRNA.
Mice were treated with a depot form of
estrogen to promote the growth of the breast cancer cells and
live tumor cell burden was monitored noninvasively with biolumi-
nescent imaging beginning 1 week after cell implantation. At this
time point, the EglN2 shRNA tumors usually exhibited stronger
luciferase signals than the control shRNA cells, arguing that
the EglN2 shRNA cells were at least as tumorigenic as the control
cells in vivo prior to the administration of doxycycline. Three days
later, imaging was repeated. Mice in which both tumors had
increased in signal intensity, indicative of tumor cell expansion,
were then fed chow containing doxycycline and serially moni-
tored using bioluminescence. Over time there was a progressive
decline in the EglN2 shRNA tumor signal relative to the control
shRNA tumor signal, largely due to continued expansion of the
tumors formed by the control shRNA cells and an apparent arrest418 Cancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc.
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Control of Cyclin D1 and Tumorigenesis by EglN2of the EglN2 shRNA cells (Figures 8C and 8D). After 5–6 weeks
of doxycycline treatment the mice were sacrificed and the
tumors were excised and weighed. Consistent with the biolumi-
nescent images, the tumors formed by the EglN2 shRNA cells
were smaller than the tumors formed by the control shRNA cells
(Figures 8E and 8F). It should be noted that bioluminescent
imaging detects viable tumor cells, whereas tumor mass
includes contributions from stroma, host cells, and nonviable
tumor cells. Similar results were observed with T47D cells (Fig-
ure S11) and MCF7 cells (Figure S12). Immunoblot analysis of
ZR75-1 tumor extracts prepared at necropsy confirmed that
Cyclin D1 levels were diminished in tumors after induction of
the EglN2 shRNAs in vivo (Figure 8G and data not shown).
Conversely, expression of Cyclin D1 under the control of a consti-
tutively active promoter restored the ability of EglN2-depleted
ZR75-1 cells to proliferate in vivo (Figure S13). Therefore, loss
of EglN2 decreases Cyclin D1 levels and inhibits tumor growth
in vivo.
Figure 6. Impaired Proliferation of Cells
Lacking EglN2 Is Due to Cyclin D1 Loss
(A and B) Immunoblot (A) and cell proliferation (B)
assay of T47D cells that were infected with retrovi
ruses encoding shRNAs against EglN2 (sequence
1 or 4) (or scrambled control) and then infected
with a retrovirus encoding HA Cyclin D1 (or empty
vector).
(C and D) Immunoblot (C) and cell proliferation
assay (D) of BT549 RB / breast carcinoma cells
infected with retroviruses encoding shRNAs
against EglN2 (sequence 1 or 4) or scrambled
control shRNA. In (D) cells were grown in Phenol
red free RPMI medium supplemented with 5%
charcoal/dextran treated FBS in the presence or
absence of estrogen (10 nM) as indicated.
(E and F) Immunoblot (E) and cell proliferation (F)
assay of T47D cells that were infected with a retro
virus encoding E7 (or empty retrovirus) and then
superinfected retroviruses encoding shRNAs
against EglN2 (sequence 4) (or scrambled control).
Note that E7 promotes the degradation of pRB
(Boyer et al., 1996) and that hyperphosphorylated
and hypophosphorylated pRB are not resolved
under these electrophoretic conditions. Error
bars represent one SEM.
DISCUSSION
We found that loss of EglN2, but not loss
of the paralogous proteins EglN1 and
EglN3, decreases Cyclin D1 mRNA and
protein levels, decreases cell prolifera-
tion, and decreases tumor formation.
Impaired proliferation in cells lacking
EglN2 could be rescued by restoring
Cyclin D1 protein production and was
not observed in cells lacking the pRB
tumor-suppressor protein, which is
required for growth inhibition in cells
deprived of Cyclin D1-associated kinase
activity. Therefore, loss of Cyclin D1
causes, and does not merely correlate with, impaired prolifera-
tion in EglN2-defective cells. An intimate, causal connection
between EglN2, Cyclin D1, and cell proliferation is also suggested
by similarities between EglN2/ mice and Cyclin D1/ mice,
both of which display impaired mammary gland proliferation in
response to pregnancy. Regulation of Cyclin D1 and cell prolifer-
ation by EglN2 depends on EglN2 catalytic activity, suggesting
that small molecule EglN2 inhibitors would have anticancer
activity.
Such inhibitors, were they to be developed, might be particu-
larly useful for the treatment of estrogen-dependent breast
cancer. Polyak and coworkers reported previously that EglN2
is estrogen inducible and that EglN2 overexpression promotes
breast cancer cell proliferation (Seth et al., 2002). The latter
observation, together with our EglN2 loss-of-function studies,
indicates that EglN2 activity regulates breast cancer proliferation
in response to estrogen. Cyclin D1, which is also induced by
estrogen, is an important regulator of breast cancer proliferationCancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc. 419
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Control of Cyclin D1 and Tumorigenesis by EglN2and is frequently amplified or otherwise overexpressed in this
disease (Roy and Thompson, 2006; Steeg and Zhou, 1998).
Loss of Cyclin D1-associated kinase activity is sufficient to
prevent or delay the development of breast cancer in mouse
models (Landis et al., 2006; Yu et al., 2001, 2006). Cyclin D1
also has kinase-independent functions related to ER signaling
and mammary epithelial proliferation (Landis et al., 2006;
Neuman et al., 1997; Yu et al., 2006; Zwijsen et al., 1997). There-
fore, EglN2 inhibitors might prove more efficacious than small
molecule inhibitors of cdk4 and cdk6, which are the catalytic
partners of Cyclin D1. Moreover, we have observed loss of the
ER in breast cancer cells deprived of EglN2 (Table S2; Q.Z.
and W.G.K., unpublished data). Therefore EglN2 antagonists
and ER antagonists might be additive or synergistic when used
to treat ER-positive breast cancers.
Downregulation of Cyclin D1 and impaired proliferation after
EglN2 loss was not restricted to breast cancer cells, however,
but appears to be common across a variety of tumor types.
Therefore, EglN2 inhibitors might be useful beyond the treatment
of ER-positive breast cancer. It will also be of interest to see if
EglN2, which maps to chromosome 19q13.2, is mutationally
activated in any human cancers.
Downregulation of EglN1, the primary HIF prolyl hydroxylase,
led to increased HIFa, as expected, but did not decrease Cyclin
D1 levels. Conversely, downregulation of EglN2 decreased
Cyclin D1 without appreciably affecting HIFa protein levels.
Moreover, downregulation of EglN2 decreased Cyclin D1 in cells
Figure 7. Impaired Fitness of Diverse
Cancer Cell Lines Lacking EglN2
(A) EglN2 mRNA abundance, as determined by
real time PCR, in U2OS cells infected with the indi
cated lentiviruses.
(B) Normalized abundance of the indicated EglN2
shRNA vectors, determined using microarray
hybridization of genomic DNA, 28 days after initial
infection with a pool containing 45,000 lentiviral
shRNA vectors and subsequent passage in vitro.
(C) EglN2 is an essential gene as determined by
the RIGER algorithm (Luo et al., 2008). The five
shRNA constructs targeting EglN2 were treated
as a set that was compared to the sets derived
from shRNA constructs targeting each of the other
9,500 genes within each of the 12 cell lines
shown in (B). A Kolmogorov Smirnov statistic
was used for assessing bias of the EglN2 shRNA
set as showing evidence of depletion during the
experiment in (B). A second application of RIGER
was then used for identifying genes commonly
essential among the 12 cell lines. The score and
rank of EglN2 from this analysis are shown. Error
bars represent one SEM.
lacking ARNT (HIF1b), the heterodimeric
partner for HIFa, and in cells lacking
pVHL, which targets hydroxylated HIFa
for destruction. These observations
strongly suggest that loss of Cyclin D1
uponEglN2 inactivation isnotasecondary
consequence of changes in HIF activity.
Nonetheless, there is the potential for
crosstalk between HIF and Cyclin D1. For example, HIF can tran-
scriptionally activate REDD1, which inhibits mTOR activity
(Brugarolas et al., 2004; Reiling and Hafen, 2004) and thereby
decreases Cyclin D1 translation. Moreover, our findings do not
in any way preclude a role for EglN2 in the regulation of HIF
activity, such as has been inferred from studies of EglN2 null
animals subjected to regional ischemia (Aragones et al., 2008).
Hypoxia generally inhibits cell proliferation associated with
a loss of cyclin D1 and pRB hypophosphorylation presumably
as a means to conserve ATP. Our findings suggest that cessation
of proliferation under these conditions is due, at least partly, to
impaired EglN2 activity. EglN inhibitors that are capable of acti-
vating the HIF transcriptional program in vivo are currently being
tested in the clinic for the treatment of anemia and ischemic
diseases. A theoretical concern with such agents relates to the
ability of HIF to promote tumor growth in some preclinical
models (Semenza, 2003). Our findings suggest that such protu-
morigenic effects might be mitigated by antitumor effects stem-
ming from downregulation of Cyclin D1.
Clearly it will be important to determine the EglN2 substrate
that links EglN2 to Cyclin D1. It should be noted that EglN2 is
a nuclear protein (Metzen et al., 2003) and regulation of Cyclin
D1 appears to be largely at the level of Cyclin D1 transcription.
The latter was unexpected because the study by Frei and Edgar
(2004) linking Egl9 to Cyclin D1 used a transgenic Drosophila
overexpressing Cyclin D1 under the control of a heterologous
promoter. It is possible that EglN2 also influences Cyclin D1420 Cancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc.
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were unrelated to the EglN2 biology described here and
therefore fortuitous. Regardless, higher metazoans, in contrast
to Drosophila and Caenorhabditis, have three EglN family
members. Our findings, together with previously published
work, indicate that EglN1 has been retained as the primary HIF
regulator under normal conditions and that EglN2 and EglN3,
in addition to regulating HIF, have assumed HIF-independent
roles in the control of proliferation and apoptosis, respectively.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa, U2OS, MEFs, UOK101, Phoenix, 293T, MCF7, ARNT / , and ARNT+/+
cells were maintained in DMEM containing 10% fetal bovine serum (FBS)
(Hyclone) except where indicated. The MCF7 media was supplemented with
Figure 8. Downregulation of EglN2
Suppresses Tumorigenesis
(A and B) Immunoblot (A) and cell proliferation
assay (B) of ZR75 1 cells infected with doxycycline
(DOX) inducible lentiviruses encoding shRNAs
against EglN2 (sequence 1 or 4) (or scrambled
control). Cells were grown in RPMI supplemented
with 10% FBS in the presence or absence of
doxycycline.
(C) Representative bioluminescent images of ortho
topic tumors formed by ZR75 1 cells as in (A) that
were then superinfected with a retrovirus encoding
firefly luciferase. A total of 8 3 106 cells were in
jected into the fourth mammary glands of nude
mice implanted with estrogen pellets. Biolumines
cent images were obtained 1 week later (day 0)
and serially after mice were begun on chow contain
ing doxycycline (day 3). Shown in (C) are the day
0 image (Before Dox) and day 35 image (After Dox).
(D) Quantitation of imaging studies as in (C).
* p < 0.01 for comparison between day 25 and
day 0; **p < 0.01 for comparison between day
35 and day 0. Error bars represent one SEM.
See Experimental Procedures for normalization.
(E) Representative gross appearance of tumors at
necropsy.
(F) Mean tumor weight at necropsy. Error bars
represent one SEM.
(G) Immunoblot analysis of tumors removed from
three mice at necropsy.
10 mg/ml insulin. 769 P, ZR 75 1, BT 474, T47D,
and BT 549 cells were maintained in RPMI
medium containing 10% FBS except where indi
cated. Following retroviral or lentiviral infection,
cells were maintained in the presence of hygrom
ycin (200 mg/ml) or puromycin (2 mg/ml) depending
on the vector. All cells were maintained at 37C in
10% CO2.
Mice
EglN2 / mice were obtained from Regeneron
Pharmaceuticals. Inguinal mammary glands were
removed one day postpartum and whole mounts
were prepared as described previously (Geng
et al., 1999). MEFs were isolated from embryonic
day13.5 embryos as described previously (Kozar
et al., 2004). All mouse experiments complied with National Institutes of Health
guidelines and were approved by the Dana Farber Cancer Institute Animal
Care and Use Committee.
siRNA
Cells grown in 6 well plates were transfected with 200 nM siRNA with Lipofect
amine2000 (for mixtures of plasmids and siRNA oligos) or Oligofectamine (for
siRNA alone). siRNAs were purchased from Dharmacon, Inc. Sense strands
were as follows: GFP, 50 GGCTACGTCCAGGAGCGCACC 30; GL3, 50 CTTAC
GCTGAGTACTTCGATT 30; GFP Scramble, 50 AACAGTCGCGTTTGCGACTG
G 30; EglN2 A, 50 GACTATATCGTGCCCTGCATG 30; EglN2 4, 50 GCCACTC
TTTGACCGGTTGCT 30; EGLN1, 50 AGCTCCTTCTACTGCTGCA 30; EGLN3,
50 CAGGTTATGTTCGCCACGT 30 (Appelhoff et al., 2004; Schlisio et al., 2008).
Immunoblot Analysis
Whole cell extracts were prepared in EBC buffer (50 mM Tris [pH 8.0], 120 mM
NaCl, and 0.5% NP40) containing protease inhibitors. Mouse mammary
glands were lysed in NP 40 lysis buffer (10% glycerol, 50 mM Tris HClCancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inc. 421
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mg/ml leupeptin and aprotinin). Equal amounts of protein, as determined by the
Bradford assay, were resolved by SDS PAGE and western blot analysis was
performed as previously described (Schlisio et al., 2008). Rabbit polyclonal
anti EglN1, EglN2, EglN3, HIF1a, and Glut1 antibodies were from Novus
Biological. Anti Cyclin D1, D2, and D3 antibodies were from Neomarker.
ARNT antibody was from BD Biosciences. Anti HA antibody was from Cova
nce. Antibodies against Vinculin, Tubulin, and FLAG (M2) were from Sigma.
Real-Time RT-PCR
Total RNA was isolated with RNeasy mini kit with on column DNase digestion
(QIAGEN). First strand cDNA was generated with the StrataScript First Stand
Synthesis System (Stratagene). Real time PCR was performed in duplicate
with QuantiTect SYBR Green PCR master mix (QIAGEN) and the Mx3000P
QPCR system (Stratagene). All values were normalized to the level of 18S
rRNA (F: 50 AAGACGATCAGATACCGTCGTAG 30; R: 50 GTTTCAGCTTTGC
AACCATACTC 30) or b actin abundance. Real time PCR primer sequences
are as follows: mouse EglN2 (F: 50 CTGGGCAACTACGTCATCAAT 30; R: 50 TG
CACCTTAACATCCCAGTTC 30); mouse Cyclin D1 (F: CCAACAACTTCCTC
TCCTGCT 30; R: 50 GACTCCAGAAGGGCTTCAATC 30); mouse b actin (F:
50 ACCAACTGGGACGACATGGA 30; R: 50 GGTCTCAAACATGATCTGGGTC
AT 30); human EglN2 (F: 50 AACATCGAGCCACTCTTTGAC 30; R: 50 TCCTT
GGCATCAAAATACCAG 30); human Cyclin D1 (F: 50 CCGTCCATGCGGAAG
ATC 30; R: 50 ATGGCCAGCGGGAAGAC 30); human b actin (F: 50 AGAAAA
TCTGGCACCACACC 30; R: 50 GGGGTGTTGAAGGTCTCAAA 30).
Plasmids
The EglN2 open reading frame cDNA was PCR amplified with a 50 primer that
introduced a BamH1 site and a Flag epitope and a 30 primer that introduced an
EcoRI site. The product was digested with BamHI and EcoRI and cloned into
pBabe Puro vector cut with these two enzymes. pBABE EglN2 H358A was
made using a site directed mutagenesis kit (Quick change; Stratagene).
pBabeHygro Cyclin D1 was constructed by ligating the BamHI SalI Cyclin
D1 cDNA insert from pBabePuro Cyclin D1 (provided by P. Sicinski) into
pBabeHygro vector cut with these two enzymes. pLXSN and pLXSN E7
retroviral vectors (Halbert et al., 1991) were given by K. Munger.
shRNA expression vectors corresponding to the siRNAs described above
were created by ligating synthetic, duplex oligonucleotides into pMKO.1 retro
viral vector (Boehm et al., 2005) or pCCLsin.PPT.hPGK.GFP.Wpre lentiviral
vector (Corso et al., 2008) (provided by S. Giordano). All plasmids were
confirmed by DNA sequencing.
Lentiviral Rb shRNA vectors, ARNT shRNA vectors, and lentiviral EglN2
shRNA (TRC00000324 328) were obtained from the Broad Institute TRC
shRNA library. Rb #1 shRNA target sequence: 50 CCACATTATTTCTAGTCCA
AA 30; Rb #2 shRNA target sequence: 50 CAGAGATCGTGTATTGAGATT 30;
ARNT target sequences: 50 CCTTTGTCTTTCTGTGTACTT 30 (Figure 1) and
50 GAGAAGTCAGATGGTTTATTT 30 (Figure S5); TRC00000324 328 shRNA
target sequences: 50 CGCATGGCAGACAGCTTAAAT 30; 50 GCTGCATCACC
TGTATCTATT 30; 50 GCCACTCTTTGACCGGTTGCT 30; 50 ACTGGGACGTTA
AGGTGCATG 30; 50 CTGGGACGTTAAGGTGCATGG 30, respectively. The
lentivirus encoding the HIF2a was a gift of S. Lee.
Virus Production and Infection
Phoenix packaging cell line was used for the generation of ecotropic retrovi
ruses and all retroviral infections were carried out as described previously
(Boehm et al., 2005). 293T packaging cell line was used for lentiviral amplifica
tion and all lentiviral infections were carried out as previously described (Moffat
et al., 2006). In brief, viruses were collected 48 and 72 hr after transfection,
filtered, and used for infecting cells in the presence of 8 mg/ml polybrene prior
to drug selection.
Microarray Analysis
The gene expression data set (www.ncbi.nlm.nih.gov/geo/; accession number
GSE5460) and immunohistochemical analysis of primary human breast tumors
used for Figure 3D was done as described in Lu et al. (2008). Raw expression
data obtained with Affymetrix GENECHIP software was normalized, analyzed,
and displayed with DNA Chip Analyzer (dChip) custom software (http://www.
dChip.org/). Array probe data were normalized to the mean expression level of422 Cancer Cell 16, 413–424, November 3, 2009 ª2009 Elsevier Inceach probe across the sample set. The analysis in Figure 3C and Figure S4 was
performed with data and software available at http://www.oncomine.org and
http://www.genesapiens.org, respectively.
For Figure S10 and Tables S1 S3, T47D breast carcinoma cells that were in
fected with lentivirus encoding either inducible EglN2 shRNA or Scrambled
control (Scr) shRNA were treated with doxycycline (1 mg/ml) for 48 hr or left
untreated. Total RNA was extracted by using RNeasy mini kit with on column
DNase digestion (QIAGEN). Biotin labeled cRNA was prepared from 1 mg of
total RNA, fragmented, and hybridized to a Human Gene 1.0ST array (Affyme
trix). The arrays were scanned and the data, as CEL files, were analyzed with
Affymetrix Expression Console. The data were normalized using RMA (Robust
Multi Array) normalization (Bolstad et al., 2003). All samples successfully
underwent a series of quality control tests and results from duplicate samples
were highly comparable (R > 0.967). Gene expression values less than
a minimum threshold of 20 or a maximum threshold of 16,000 were set to
20 and 16,000, respectively. Genes with minimal variation across the data
set were discarded (maximum/minimum < 3 or maximum minimum < 100).
GSEA was performed as described previously (Subramanian et al., 2005).
Cell Proliferation Assays
T47D, BT 474, and ZR 75 1 cells were plated, in triplicate, in 6 well plates
(105 cells/well) in RPMI supplemented with 10% FBS or in phenol red free
RPMI containing 5% charcoal stripped serum supplemented, as indicated,
with 10 nM estrogen. At the indicated time points, cells were trypsinized,
pelleted by centrifugation, and resuspended in RPMI supplemented with
0.2% Trypan blue. The number of viable cells, as determined by Trypan blue
exclusion, was determined with a hemocytometer.
shRNA Pooled Screening
Pooled RNAi screens consisting of 45,000 shRNAs were conducted as
described by Luo et al. (2008). In brief, an shRNA pool consisting of 45,182
individual constructs was infected into the indicated cancer cell lines. For
each screen, 3.6 3 107 cells were infected at a multiplicity of infection of
0.3 for ensuring that each shRNA was introduced into 200 independent cells.
Early time point (3 4 day) samples (n = 10) and DNA control samples (n = 10)
were compared with end time point (4 weeks) samples derived from replicate
(n = 10) infections of each cell line. Genomic DNA was prepared from these
time points and the hairpin region of shRNA constructs was amplified and
digested to create half hairpin barcodes that were hybridized to a custom
Affymetrix microarray. After microarray normalization, fold depletion scores
for EglN2 were calculated on a construct by construct basis by comparing
late time point hybridization values to early time point hybridization values.
RIGER Algorithm
RNAi gene enrichment ranking (RIGER), a statistical approach that considers
the phenotypic results for the multiple shRNA constructs targeting the same
gene, was deployed as described (Luo et al., 2008). Briefly, this approach is
based on the GSEA methodology (Subramanian et al., 2005) and uses similar
Kolmogorov Smirnov based statistics to calculate gene scores from a data
set of shRNA construct profiles. First, shRNA constructs targeting EglN2
were scored according to their differential effects between late and early
time points for each cell line. An Enrichment Score was calculated for each
cell line, indicating the enrichment or depletion for the five EglN2 hairpins
treated as a set. Finally, to find genes frequently essential across multiple
cell lines, a second application of RIGER was used to find genes for which
the hairpins targeting the gene were depleted in at least 8/12 cell lines.
Orthotopic Tumor Growth Assays
Six week old female nude mice (Taconic) were used for xenograft studies.
Approximately 8 3 106 viable tumor cells were resuspended in 40 ml growth
factor reduced Matrigel (BD Biosciences) and injected orthotopically into
mammary gland four as previously described (Minn et al., 2005). Mice were
supplied with chow containing 6 g doxycycline/kg (Bioserv) for a treatment
period of 5 6 weeks.
For bioluminescent detection and quantification of cancer cells, mice were
given a single i.p. injection of a mixture of luciferin (50 mg/kg), ketamine
(150 mg/kg), and xylazine (12 mg/kg) in sterile water. Five minutes later,
mice were placed in a light tight chamber equipped with a charge coupled.
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Control of Cyclin D1 and Tumorigenesis by EglN2device IVIS imaging camera (Xenogen). Photons were collected for a period of
1 60 s, and images were obtained by using LIVING IMAGE 2.60.1 software
(Xenogen) and quantified using IGOR Pro 4.09A image analysis software
(WaveMatrics). The total photons from the EglN2 shRNA tumor region of
interest (ROI) were divided by the total photons from Scrambled shRNA tumor
ROI and, for each mouse, normalized based on the ratio prior to the onset of
doxycycline treatment for that mouse. Results were presented as mean ±
standard error of the mean (SEM).
ACCESSION NUMBERS
Microarray data from T47D cells harvested 0 or 48 hr after induction of an
shRNA against EglN2 or a scrambled control shRNA were deposited in the
NIH Gene Expression Omnibus database (accession number GSE18171).
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